INGN Stock Overview
A medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Inogen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.50 |
| 52 Week High | US$13.33 |
| 52 Week Low | US$5.08 |
| Beta | 1.03 |
| 1 Month Change | -10.71% |
| 3 Month Change | -20.93% |
| 1 Year Change | 46.30% |
| 3 Year Change | -74.00% |
| 5 Year Change | -88.11% |
| Change since IPO | -43.89% |
Recent News & Updates
Recent updates
Inogen: Upside Seems Limited After Big Move Up
Sep 24Inogen, Inc.'s (NASDAQ:INGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Jul 16
Inogen: Improving, But Still Struggling For Air
Jul 01Inogen, Inc. (NASDAQ:INGN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
May 22Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities
Apr 13Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target
Mar 01Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%
Feb 01Is Inogen (NASDAQ:INGN) In A Good Position To Deliver On Growth Plans?
Oct 06Inogen (NASDAQ:INGN) Is In A Strong Position To Grow Its Business
Jun 21Is Inogen, Inc. (NASDAQ:INGN) Worth US$13.3 Based On Its Intrinsic Value?
Mar 14Companies Like Inogen (NASDAQ:INGN) Can Afford To Invest In Growth
Oct 27Inogen, Inc.'s (NASDAQ:INGN) Intrinsic Value Is Potentially 64% Above Its Share Price
Sep 20Inogen: Structural, Supply Chain Headwinds Remain
Sep 13Inogen Non-GAAP EPS of -$0.02 beats by $0.31, revenue of $103.38M beats by $2.74M
Aug 04Inogen: Seasonal FCF, Tightening Margins, Supply Chain Headwinds
Jun 14At US$35.28, Is It Time To Put Inogen, Inc. (NASDAQ:INGN) On Your Watch List?
Apr 03Hammered By Supply Issues, Inogen Could Be A 2023 Comeback Story
Mar 31Is There An Opportunity With Inogen, Inc.'s (NASDAQ:INGN) 28% Undervaluation?
Mar 09Shareholder Returns
| INGN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -11.8% | -1.3% | 0.1% |
| 1Y | 46.3% | 12.2% | 26.1% |
Return vs Industry: INGN exceeded the US Medical Equipment industry which returned 12.2% over the past year.
Return vs Market: INGN exceeded the US Market which returned 26.1% over the past year.
Price Volatility
| INGN volatility | |
|---|---|
| INGN Average Weekly Movement | 7.4% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: INGN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 834 | Kevin R. Smith | www.inogen.com |
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories.
Inogen, Inc. Fundamentals Summary
| INGN fundamental statistics | |
|---|---|
| Market cap | US$217.22m |
| Earnings (TTM) | -US$52.69m |
| Revenue (TTM) | US$331.52m |
0.6x
P/S Ratio-3.8x
P/E RatioIs INGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INGN income statement (TTM) | |
|---|---|
| Revenue | US$331.52m |
| Cost of Revenue | US$184.91m |
| Gross Profit | US$146.61m |
| Other Expenses | US$199.30m |
| Earnings | -US$52.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.21 |
| Gross Margin | 44.22% |
| Net Profit Margin | -15.89% |
| Debt/Equity Ratio | 0% |
How did INGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 01:25 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Inogen, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Marcus | J.P. Morgan |
| Matthew Mishan | KeyBanc Capital Markets Inc. |
| Jeffrey Cohen | Ladenburg Thalmann & Company |